## Antonia K Roseweir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/554303/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of Potent Kisspeptin Antagonists Delineate Physiological Mechanisms of Gonadotropin Regulation. Journal of Neuroscience, 2009, 29, 3920-3929.	1.7	322
2	Mannose impairs tumour growth and enhances chemotherapy. Nature, 2018, 563, 719-723.	13.7	282
3	Kisspeptin Is Essential for the Full Preovulatory LH Surge and Stimulates GnRH Release from the Isolated Ovine Median Eminence. Endocrinology, 2011, 152, 1001-1012.	1.4	210
4	Kisspeptin Signalling in the Hypothalamic Arcuate Nucleus Regulates GnRH Pulse Generator Frequency in the Rat. PLoS ONE, 2009, 4, e8334.	1.1	163
5	The role of kisspeptin in the control of gonadotrophin secretion. Human Reproduction Update, 2008, 15, 203-212.	5.2	161
6	Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1228-E1236.	1.8	154
7	Kisspeptin antagonists: Unraveling the role of kisspeptin in reproductive physiology. Brain Research, 2010, 1364, 81-89.	1.1	58
8	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clinical Science, 2019, 133, 181-193.	1.8	51
9	Kisspeptin-10 Inhibits Angiogenesis in Human Placental Vessels ex Vivo and Endothelial Cells in Vitro. Endocrinology, 2010, 151, 5927-5934.	1.4	48
10	The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 4397-4404.	0.7	47
11	The role of gamma delta T lymphocytes in breast cancer: a review. Translational Research, 2019, 203, 88-96.	2.2	46
12	A role for kisspeptins in pregnancy: facts and speculations. Reproduction, 2009, 138, 1-7.	1.1	42
13	Kisspeptin-10 inhibits cell migration inÂvitro via a receptor-GSK3 beta-FAK feedback loop in HTR8SVneo cells. Placenta, 2012, 33, 408-415.	0.7	42
14	Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cellular Signalling, 2019, 56, 15-22.	1.7	38
15	Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treatment Reviews, 2017, 57, 1-7.	3.4	36
16	Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 2016, 16, 229.	1.1	30
17	A novel tumorâ€based epithelialâ€toâ€mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. International Journal of Cancer, 2019, 144, 150-159.	2.3	28
18	The NF-KB pathway and endocrine therapy resistance in breast cancer. Endocrine-Related Cancer, 2019, 26, R369-R380.	1.6	19

## Antonia K Roseweir

#	Article	IF	CITATIONS
19	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 283-296.	1.3	17
20	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2021, 7, 121-134.	1.3	17
21	Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. Molecular Carcinogenesis, 2016, 55, 1667-1677.	1.3	12
22	Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer. Oncotarget, 2016, 7, 70601-70612.	0.8	12
23	ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. British Journal of Cancer, 2018, 119, 323-329.	2.9	11
24	Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: Implications for treatment. Cellular Signalling, 2019, 54, 81-90.	1.7	11
25	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 2021, 124, 786-796.	2.9	11
26	The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. International Journal of Cancer, 2019, 144, 2320-2329.	2.3	10
27	The Prognostic Role of the Non-Canonical Nuclear Factor-Kappa B Pathway in Renal Cell Carcinoma Patients. Urologia Internationalis, 2018, 101, 190-196.	0.6	9
28	Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. Journal of the National Cancer Institute, 2018, 110, 616-627.	3.0	8
29	The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer. Cellular Signalling, 2019, 60, 91-99.	1.7	7
30	Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 2017, 8, 37172-37185.	0.8	6
31	Determining the prognostic significance of IKKα in prostate cancer. Prostate, 2020, 80, 1188-1202.	1.2	5
32	Neuroendocrine GPCR Signaling. , 2012, , 21-53.		4
33	The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. Human Pathology, 2022, 127, 1-11.	1.1	2
34	The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer Journal of Clinical Oncology, 2019, 37, 581-581.	0.8	1
35	Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer― British Journal of Cancer, 2018, 119, 909-909.	2.9	0
36	The relationship between the non-canonical NF-κB pathway, tumour microenvironment, systemic inflammation and survival in patients undergoing surgery for colorectal caner Journal of Clinical Oncology, 2017, 35, 631-631.	0.8	0

Antonia K Roseweir

#	Article	IF	CITATIONS
37	Phenotypic subtypes and risk of local recurrence after radical resection for rectal cancer Journal of Clinical Oncology, 2018, 36, 637-637.	0.8	Ο
38	Phenotypic subtypes as a novel validated prognostic classification system for patients with colorectal cancer Journal of Clinical Oncology, 2018, 36, 625-625.	0.8	0
39	Comorbidity and systemic inflammation are independent prognostic factors in patients with colorectal cancer: A ScotScan collaborative study Journal of Clinical Oncology, 2019, 37, 707-707.	0.8	0
40	Validation of the Glasgow Microenvironment Score in patients with colon cancer: A pathology-based prognostic tool Journal of Clinical Oncology, 2020, 38, 206-206.	0.8	0
41	Prognostic phenotypic subtypes to predict recurrence and response to adjuvant chemotherapy for colorectal cancer Journal of Clinical Oncology, 2020, 38, 205-205.	0.8	0
42	Effect of phenotype on outcome in synchronously resected primary colorectal cancer and matched liver metastases Journal of Clinical Oncology, 2020, 38, 221-221.	0.8	0
43	Local immune response in colon cancer: Indicative of good or poor prognosis?. Journal of Clinical Oncology, 2020, 38, 213-213.	0.8	0